Q1: 2026-05-11 Earnings Summary
EPS of -$0.93 misses by $0.28
|
Revenue of
$0.00
beats by $0.00
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call May 11, 2026 8:30 AM EDT
Company Participants
Rachel Frank
Claire Mazumdar Clemon - CEO & Director
Bill Schelman - Chief Medical Officer
Ryan Cohlhepp - President, COO & Director
Ivan Hyep - CFO & Treasurer
Conference Call Participants
Eric Schmidt - Cantor Fitzgerald & Co., Research Division
Tyler Van Buren - TD Cowen, Research Division
Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division
Kelsey Goodwin - Piper Sandler & Co., Research Division
Bradley Canino - Guggenheim Securities, LLC, Research Division
Judah Frommer - Morgan Stanley, Research Division
Reni Benjamin - Citizens JMP Securities, LLC, Research Division
Jeet Mukherjee - BTIG, LLC, Research Division
Boris Peaker - JonesTrading Institutional Services, LLC, Research Division
Joseph Catanzaro - Mizuho Securities USA LLC, Research Division
Jin Law - Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Bicara Therapeutics First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Rachel Frank, Vice President of Investor Relations and Corporate Communications. Please go ahead.
Rachel Frank
Thank you, and good morning, everyone. It's a pleasure to welcome you to Bicara Therapeutics First Quarter 2026 Earnings Call. Earlier this morning, we issued a press release highlighting results from the quarter and recent business progress. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website.
Before we begin, please note that this call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please refer to our most recent SEC filings for important risk factors that could cause our actual performance and results to materially differ
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。